Landscapes / Companies
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 approved
1 in Phase 1
Drugs
3
in active trials · 8 in all
Trials
6 active
12 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
Approved | 27 Nov 2026soonPhase 1 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 27 Nov 2026 · Phase 1 trial completes | ||||
| Also tested for | Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) and 2 more | ||||
| Open drug page | |||||
Gamma secretase inhibitor |
Approved | 28 May 2027Phase 2 trial completes | |||
| Next date | 28 May 2027 · Phase 2 trial completes | ||||
| Also tested for | Desmoid Tumor, Aggressive Fibromatosis | ||||
| Open drug page | |||||
— |
Phase 1 | 18 Jan 2027Phase 1 trial completes | |||
| Next date | 18 Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Mesothelioma, Malignant | ||||
| Open drug page | |||||
About
- No active trial
- Brimarafenib, Mirdametinib and Carbamazepine, Nirogacestat and Cocktail of CYP Specific Probe Substrates, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021